New hope for lymphoma patients: skipping chemo?
NCT ID NCT06263491
Summary
This study is testing whether a combination of two drugs, pirtobrutinib and rituximab, can provide long-term remission for people newly diagnosed with a slower-growing form of mantle cell lymphoma (MCL) without using traditional chemotherapy. It will enroll 50 adults with low or intermediate-risk MCL who have not had any prior treatment. The main goals are to see how well the treatment works and to monitor its safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.